Craig Hallum started coverage on shares of Alpha Teknova (NASDAQ:TKNO - Free Report) in a research note released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price target on the stock.
Alpha Teknova Stock Up 3.2 %
Shares of NASDAQ:TKNO traded up $0.26 during trading hours on Monday, reaching $8.31. The stock had a trading volume of 155,687 shares, compared to its average volume of 225,355. The stock has a market capitalization of $442.74 million, a price-to-earnings ratio of -11.22 and a beta of 0.34. The firm's 50 day moving average is $8.48 and its 200-day moving average is $6.54. Alpha Teknova has a 1 year low of $1.15 and a 1 year high of $10.37. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.94 and a current ratio of 4.73.
Institutional Trading of Alpha Teknova
Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its position in shares of Alpha Teknova by 622.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,400 shares of the company's stock worth $37,000 after acquiring an additional 3,791 shares in the last quarter. Mount Lucas Management LP acquired a new stake in Alpha Teknova during the fourth quarter worth approximately $75,000. China Universal Asset Management Co. Ltd. acquired a new stake in Alpha Teknova during the fourth quarter worth approximately $94,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Alpha Teknova during the 4th quarter worth approximately $180,000. Finally, Whalen Wealth Management Inc. acquired a new position in shares of Alpha Teknova in the 4th quarter valued at $240,000. 13.81% of the stock is owned by hedge funds and other institutional investors.
Alpha Teknova Company Profile
(
Get Free Report)
Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.
See Also
Before you consider Alpha Teknova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Teknova wasn't on the list.
While Alpha Teknova currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
